SAN DIEGO, Sept. 24, 2014 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and age-related macular degeneration, today announced that results for patients with platinum-resistant ovarian cancer who participated in either a Phase 2 clinical trial of TRC105 as a single agent or a Phase 1/2 clinical trial of TRC105 in combination with Avastin® (bevacizumab) will be presented at the 2014 Annual Meeting of the European Society for Medical Oncology (ESMO) being held from September 26th-30th in Madrid, Spain.

The ESMO presentation details are as follows:

Abstract Number: 887P
Abstract Title: TRC105 (anti-endoglin antibody) in Combination with Bevacizumab and as a Single Agent for Platinum Resistant Ovarian Cancer
Presenter: Agustin Garcia, M.D., Keck School of Medicine, University of Southern California
Session: Poster Display Session – Anti-Cancer Agents & Biologic Therapy – Ovarian Cancer
Date: Saturday, September 27, 2014
Time: 12:45 – 13:45 local time

About TRC105

TRC105 is a novel, clinical stage antibody to endoglin, which is a protein that is overexpressed on endothelial cells and is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in clinical trials sponsored by both TRACON and the National Cancer Institute for the treatment of multiple solid tumor types in combination with VEGF inhibitors. TRC105 is also expected to be studied in combination with VEGF inhibitor treatments in age‐related macular degeneration.  For more information about the clinical trials, please visit TRACON's website at


TRACON develops targeted therapies for cancer and age-related macular degeneration. TRACON's current pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. Both TRC105 and TRC102 are being developed for treatment in combination with currently available therapies. To learn more about TRACON and its product candidates, visit TRACON's website at

Casey Logan
Chief Business Officer
(858) 550-0780 ext. 236